BridgeBio Pharma, Inc.
BBIO
株式のランク
#1620
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying,... BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
株価
$68.06
時価総額
$13.31B
変化（1日）
2.52%
変化（1年）
23.93%
国
US
取引 BridgeBio Pharma, Inc. (BBIO)
カテゴリー
Healthcare
BridgeBio Pharma, Inc.（BBIO）の配当履歴
BridgeBio Pharma, Inc.（証券コード：BBIO）は合計で0回の配当を行いました。
すべての配当の合計（株式分割調整済み）は：0.00
配当利回り（TTM）：0
すべての配当の合計（株式分割調整済み）は：0.00
配当利回り（TTM）：0
2026から2026までのBridgeBio Pharma, Inc.（BBIO）の配当履歴
年間配当支払い
| 年 | 配当（株式分割調整済み） | 変化 |
|---|---|---|
| 提供された日付のデータは十分ではありません。 | ||
すべての配当支払いの一覧
| 年 | 配当 | 変化 |
|---|---|---|
| 提供された日付のデータは十分ではありません。 | ||
同業他社や競合企業の配当履歴
| 企業 | 配当支払い回数 | 国 |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
